FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386758376> ?p ?o ?g. }

• W4386758376 abstract "Abstract Background Outcomes for children with relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are poor, and new therapies are needed. Pevonedistat is an inhibitor of the NEDD‐8 activating enzyme, a key regulator of the ubiquitin proteasome system that is responsible for protein turnover, with protein degradation regulating cell growth and survival. Procedure We evaluated the feasibility, toxicity, and pharmacokinetics (PK) of pevonedistat (20 mg/m 2 days 1, 3, 5) in combination with azacitidine, fludarabine, cytarabine (aza‐FLA) in children with R/R AML and MDS (NCT03813147). Twelve patients were enrolled, median age was 13 years (range 1–21). Median number of prior chemotherapeutic regimens was two (range one to five), and two (25%) patients had prior hematopoietic cell transplantation. Diagnoses were AML NOS ( n = 10, 83%), acute monocytic leukemia ( n = 1), and therapy‐related AML ( n = 1). Results Overall, three of 12 (25%) patients experienced DLTs. The day 1 mean ± SD ( n = 12) C max , V SS , T 1/2 , and CL were 223 ± 91 ng/mL, 104 ± 53.8 L/m 2 , 4.3 ± 1.2 hours, and 23.2 ± 6.9 L/h/m 2 , respectively. T 1/2 , V SS , and C max , but not CL, were significantly different between age groups. The overall response rate was 25%, with n = 3 patients achieving a complete remission with incomplete hematologic recovery (CRi). Conclusions Pevonedistat 20 mg/m 2 combined with Aza‐FLA was tolerable in children with R/R AML with similar toxicity profile to other intensive AML regimens. However, within the confines of a phase 1 study, we did not observe that the pevonedistat + Aza‐FLA combination demonstrated significant anti‐leukemic activity." @default.
• W4386758376 created "2023-09-16" @default.
• W4386758376 creator A5007563936 @default.
• W4386758376 creator A5027416118 @default.
• W4386758376 creator A5038841996 @default.
• W4386758376 creator A5046174386 @default.
• W4386758376 creator A5050571054 @default.
• W4386758376 creator A5050738935 @default.
• W4386758376 creator A5051375301 @default.
• W4386758376 creator A5067486820 @default.
• W4386758376 creator A5081153366 @default.
• W4386758376 date "2023-09-14" @default.
• W4386758376 modified "2023-10-01" @default.
• W4386758376 title "Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712" @default.
• W4386758376 cites W1968887194 @default.
• W4386758376 cites W2021846401 @default.
• W4386758376 cites W2050259155 @default.
• W4386758376 cites W2076194625 @default.
• W4386758376 cites W2104438003 @default.
• W4386758376 cites W2121565126 @default.
• W4386758376 cites W2132693111 @default.
• W4386758376 cites W2159507916 @default.
• W4386758376 cites W2278901087 @default.
• W4386758376 cites W2507754954 @default.
• W4386758376 cites W2773514102 @default.
• W4386758376 cites W2790863839 @default.
• W4386758376 cites W2807351465 @default.
• W4386758376 cites W2899304092 @default.
• W4386758376 cites W2912124132 @default.
• W4386758376 cites W2964979481 @default.
• W4386758376 cites W3004873674 @default.
• W4386758376 cites W3016775247 @default.
• W4386758376 cites W3025300208 @default.
• W4386758376 cites W3163024322 @default.
• W4386758376 cites W4376595466 @default.
• W4386758376 doi "https://doi.org/10.1002/pbc.30672" @default.
• W4386758376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37710306" @default.
• W4386758376 hasPublicationYear "2023" @default.
• W4386758376 type Work @default.
• W4386758376 citedByCount "0" @default.
• W4386758376 crossrefType "journal-article" @default.
• W4386758376 hasAuthorship W4386758376A5007563936 @default.
• W4386758376 hasAuthorship W4386758376A5027416118 @default.
• W4386758376 hasAuthorship W4386758376A5038841996 @default.
• W4386758376 hasAuthorship W4386758376A5046174386 @default.
• W4386758376 hasAuthorship W4386758376A5050571054 @default.
• W4386758376 hasAuthorship W4386758376A5050738935 @default.
• W4386758376 hasAuthorship W4386758376A5051375301 @default.
• W4386758376 hasAuthorship W4386758376A5067486820 @default.
• W4386758376 hasAuthorship W4386758376A5081153366 @default.
• W4386758376 hasConcept C104317684 @default.
• W4386758376 hasConcept C126322002 @default.
• W4386758376 hasConcept C142424586 @default.
• W4386758376 hasConcept C143998085 @default.
• W4386758376 hasConcept C150194340 @default.
• W4386758376 hasConcept C190727270 @default.
• W4386758376 hasConcept C2776063141 @default.
• W4386758376 hasConcept C2776239401 @default.
• W4386758376 hasConcept C2776364478 @default.
• W4386758376 hasConcept C2776694085 @default.
• W4386758376 hasConcept C2776755627 @default.
• W4386758376 hasConcept C2777408962 @default.
• W4386758376 hasConcept C2778041864 @default.
• W4386758376 hasConcept C2778729363 @default.
• W4386758376 hasConcept C2779263901 @default.
• W4386758376 hasConcept C2779282312 @default.
• W4386758376 hasConcept C2780007613 @default.
• W4386758376 hasConcept C2780817109 @default.
• W4386758376 hasConcept C2911091166 @default.
• W4386758376 hasConcept C55493867 @default.
• W4386758376 hasConcept C71924100 @default.
• W4386758376 hasConcept C86803240 @default.
• W4386758376 hasConcept C87355193 @default.
• W4386758376 hasConcept C90924648 @default.
• W4386758376 hasConceptScore W4386758376C104317684 @default.
• W4386758376 hasConceptScore W4386758376C126322002 @default.
• W4386758376 hasConceptScore W4386758376C142424586 @default.
• W4386758376 hasConceptScore W4386758376C143998085 @default.
• W4386758376 hasConceptScore W4386758376C150194340 @default.
• W4386758376 hasConceptScore W4386758376C190727270 @default.
• W4386758376 hasConceptScore W4386758376C2776063141 @default.
• W4386758376 hasConceptScore W4386758376C2776239401 @default.
• W4386758376 hasConceptScore W4386758376C2776364478 @default.
• W4386758376 hasConceptScore W4386758376C2776694085 @default.
• W4386758376 hasConceptScore W4386758376C2776755627 @default.
• W4386758376 hasConceptScore W4386758376C2777408962 @default.
• W4386758376 hasConceptScore W4386758376C2778041864 @default.
• W4386758376 hasConceptScore W4386758376C2778729363 @default.
• W4386758376 hasConceptScore W4386758376C2779263901 @default.
• W4386758376 hasConceptScore W4386758376C2779282312 @default.
• W4386758376 hasConceptScore W4386758376C2780007613 @default.
• W4386758376 hasConceptScore W4386758376C2780817109 @default.
• W4386758376 hasConceptScore W4386758376C2911091166 @default.
• W4386758376 hasConceptScore W4386758376C55493867 @default.
• W4386758376 hasConceptScore W4386758376C71924100 @default.
• W4386758376 hasConceptScore W4386758376C86803240 @default.
• W4386758376 hasConceptScore W4386758376C87355193 @default.
• W4386758376 hasConceptScore W4386758376C90924648 @default.
• W4386758376 hasFunder F4320337351 @default.
• W4386758376 hasFunder F4320337354 @default.

• next